Community pharmacy naloxone supply, before and after rescheduling as an over-the-counter drug: sales and prescriptions data, 2014-2018
- PMID: 32124984
- DOI: 10.5694/mja2.50524
Community pharmacy naloxone supply, before and after rescheduling as an over-the-counter drug: sales and prescriptions data, 2014-2018
Abstract
Objectives: To characterise the community pharmacy supply of naloxone by supply type - individual prescription, prescriber bag, and non-dispensed (supplied over the counter or expired) - during 2014-2018; to examine whether the 2016 rescheduling of naloxone as an over-the-counter drug influenced non-dispensed naloxone supply volume.
Design, setting: Analysis of monthly naloxone prescriptions (Pharmaceutical Benefits Scheme) and sales data (IQVIA), 2014-2018, for Australia and by state and territory; time series analysis of non-dispensed naloxone supply to assess effect of rescheduling on naloxone supply.
Major outcomes: Total naloxone supply to community pharmacies; prescribed and non-dispensed naloxone supply.
Results: During 2014-2018, 372 351 400 μg units of naloxone were sold to community pharmacies: non-dispensed naloxone accounted for 205 866.5 units (55.3%), prescriber bags for 155 841 units (41.8%), and individual prescriptions for 10 643.5 units (2.9%). Population-adjusted national naloxone sales to community pharmacies increased between 2014 and 2018 (per year: incidence rate ratio [IRR], 1.15; 95% CI, 1.09-2.22). This increase was primarily attributable to increased volumes of prescriber bag naloxone (IRR, 1.63; 95% CI, 1.50-1.78) and, to a lesser extent, increased individual prescription supply (IRR, 2.04; 95% CI, 1.85-2.26). Non-dispensed naloxone supply volume was unchanged at the national level (IRR, 0.93; 95% CI, 0.85-1.01); changes in non-dispensed supply immediately following rescheduling and subsequently were not statistically significant in time series analyses for most jurisdictions.
Conclusions: Total naloxone supply to community pharmacies in Australia increased between 2014 and 2018, but rescheduling that enabled over-the-counter access did not significantly influence the volume of non-dispensed naloxone.
Keywords: Drug overdose; Opioid-related disorders; Overdose; Preventive medicine.
© 2020 AMPCo Pty Ltd.
Comment in
-
Providing take home naloxone needs to be improved to prevent opioid overdose deaths.Med J Aust. 2020 Apr;212(7):307-308. doi: 10.5694/mja2.50561. Epub 2020 Mar 24. Med J Aust. 2020. PMID: 32207143 No abstract available.
References
-
- Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy 2019; 71: 183-188.
-
- Langham S, Wright A, Kenworthy J, et al. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value Health 2018; 21: 407-415.
-
- Clark KA, Wilder MC, Winstanley LE. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8: 153-163.
-
- Ashrafioun L, Gamble S, Herrmann M, Baciewicz G. Evaluation of knowledge and confidence following opioid overdose prevention training: a comparison of types of training participants and naloxone administration methods. Subst Abuse 2016; 37: 76-81.
-
- Dietze PM, Stare M, Cogger S, et al. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: variations across capital cities. Drug Alcohol Rev 2018; 37: 457-463.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
